BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 29019414)

  • 21. GFRA3 promoter methylation may be associated with decreased postoperative survival in gastric cancer.
    Eftang LL; Klajic J; Kristensen VN; Tost J; Esbensen QY; Blom GP; Bukholm IR; Bukholm G
    BMC Cancer; 2016 Mar; 16():225. PubMed ID: 26984265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silenced ZNF154 Is Associated with Longer Survival in Resectable Pancreatic Cancer.
    Wiesmueller F; Kopke J; Aust D; Roy J; Dahl A; Pilarsky C; Grützmann R
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31683647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer.
    Lando M; Fjeldbo CS; Wilting SM; C Snoek B; Aarnes EK; Forsberg MF; Kristensen GB; Steenbergen RD; Lyng H
    Epigenetics; 2015; 10(10):970-80. PubMed ID: 26291246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
    Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
    Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heme oxygenase-1 promoter polymorphism is a predictor of disease relapse in pancreatic neuroendocrine tumors.
    Vashist YK; Uzunoglu G; Deutsch L; Kalinin V; Zehler O; Alzadjali A; Kutup A; Izbicki JR; Yekebas EF
    J Surg Res; 2011 Apr; 166(2):e121-7. PubMed ID: 21236443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer.
    Aghdassi A; Sendler M; Guenther A; Mayerle J; Behn CO; Heidecke CD; Friess H; Büchler M; Evert M; Lerch MM; Weiss FU
    Gut; 2012 Mar; 61(3):439-48. PubMed ID: 22147512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Negative methylation status of vimentin predicts improved prognosis in pancreatic carcinoma.
    Zhou YF; Xu W; Wang X; Sun JS; Xiang JJ; Li ZS; Zhang XF
    World J Gastroenterol; 2014 Sep; 20(36):13172-7. PubMed ID: 25278713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer.
    Tang B; Li Y; Qi G; Yuan S; Wang Z; Yu S; Li B; He S
    Sci Rep; 2015 Sep; 5():13563. PubMed ID: 26338139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival.
    Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M
    Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential DNA Methylation of THOR and
    Ott P; Araúzo-Bravo MJ; Hoffmann MJ; Poyet C; Bendhack ML; Santourlidis S; Erichsen L
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
    Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
    Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TERT Promoter Mutations and Risk of Recurrence in Meningioma.
    Sahm F; Schrimpf D; Olar A; Koelsche C; Reuss D; Bissel J; Kratz A; Capper D; Schefzyk S; Hielscher T; Wang Q; Sulman EP; Adeberg S; Koch A; Okuducu AF; Brehmer S; Schittenhelm J; Becker A; Brokinkel B; Schmidt M; Ull T; Gousias K; Kessler AF; Lamszus K; Debus J; Mawrin C; Kim YJ; Simon M; Ketter R; Paulus W; Aldape KD; Herold-Mende C; von Deimling A
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26668184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Relevance of Plasma DNA Methylation in Colorectal Cancer Patients Identified by Using a Genome-Wide High-Resolution Array.
    Lin PC; Lin JK; Lin CH; Lin HH; Yang SH; Jiang JK; Chen WS; Chou CC; Tsai SF; Chang SC
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1419-27. PubMed ID: 25472652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
    Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
    Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma.
    Henriksen SD; Madsen PH; Larsen AC; Johansen MB; Drewes AM; Pedersen IS; Krarup H; Thorlacius-Ussing O
    Clin Epigenetics; 2016; 8():117. PubMed ID: 27891190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating the clinical feasibility: The direct bisulfite genomic sequencing for examination of methylated status of protocadherin10 (PCDH10) promoter to predict the prognosis of gastric cancer.
    Hou YC; Deng JY; Zhang RP; Xie XM; Cui JL; Wu WP; Hao XS; Liang H
    Cancer Biomark; 2015; 15(5):567-73. PubMed ID: 26406945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.
    Shin SH; Kim HJ; Hwang DW; Lee JH; Song KB; Jun E; Shim IK; Hong SM; Kim HJ; Park KM; Lee YJ; Kim SC
    Oncotarget; 2017 Mar; 8(11):17945-17959. PubMed ID: 28160547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
    Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
    Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma.
    Ling Q; Xu X; Ye P; Xie H; Gao F; Hu Q; Liu Z; Wei X; Röder C; Trauzold A; Kalthoff H; Zheng S
    Oncotarget; 2017 Feb; 8(9):15159-15167. PubMed ID: 28122349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.